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Although nanodiamonds have long being considered as a potential tool for 
biomedical research, the practical in vivo application of nanodiamonds remains 
relatively unexplored. In this paper, we present the first application of in vivo MRI 
contrast enhancement using only iron embedded magnetic nanodiamonds. MR image 
enhancement was clearly demonstrated in the rendering of T2-weighted images of mice 
obtained using an unmodified commercial MRI scanner. The excellent contrast 
obtained using these nanodiamonds opens the door to the non-invasive in vivo tracking 
of NDs and image enhancement. In the future, one can apply these magnetic 
nanodiamonds together with surface modifications to facilitate drug delivery, targeted 
therapy, localized thermal treatment, and diagnostic imaging. 
 
 
Introduction 
 
Nanodiamonds (NDs) are highly valued for use in a variety of fields, such as 
lubricant additives1, electronics devices for energy harvesting2, slow-neutron reflectors3, 
and biomedical applications4,5. The outstanding bio-compatibility of NDs make them 
ideal for drug delivery6, anticancer therapy7, tooth and bone implants8, antimicrobial 
agents9 and labeling10. ND labeling applications can be divided into two main 
categories: light-based methods (e.g., fluorescence imaging11, near-infrared imaging12, 
and photoacoustic imaging13) and magnetic resonance imaging14-17 (MRI). When using 
light-based methods, defects within the diamond facilitate the emission of light and in 
so doing overcome many of the difficulties involved in detection. More than one 
hundred types of diamond defect have been identified18, covering the entire visible 
spectrum. The most well-known defects are the silicon vacancy center and the nitrogen 
vacancy (NV) center, which produce emissions in the red region (600 ~ 800 nm), 
making them highly visible in fluorescence microscopy19. Unlike chemical dyes, the 
fluorescence of diamonds does not diminish over time, which makes them ideal for 
experiments of extended duration. In a previous paper, we presented iron embedded 
magnetic NDs associated with NV centers, which are compatible with existing 
fluorescence observation technology as a potential dual functional in vivo tracer20. 
Nonetheless, the in vivo imaging of NDs is still limited to regions that are optically 
accessible, i.e., only few centimeters from the surface. Imaging deep within the body 
requires MRI. 
The ability to differentiate between normal and tumor tissue makes MRI a powerful 
diagnostic tool. Furthermore, MRI is noninvasive. Nonetheless, obtaining reliable 
images depends on the use of contrast agents. Two ND-based methods have been 
developed to enhance the contrast of MRI images. The first method involves attaching 
magnetic elements17,21 (Gd or Mn complex) to the surface of NDs. The second method 
involves hyperpolarizing the NDs via the Overhauser effect16. Unfortunately, both of 
these methods necessitate complex chemical synthesis processes or specially designed 
ultra-low magnetic field MRI scanners. At present, there is a notable lack of research 
on in vivo MRI contrast enhancement methods using only NDs. In fact, the in vivo use 
of NDs is rare. 
Ion implantation is a mature technology, which has been used in the semiconductor 
industry for more than 50 years22. This method involves the insertion of atoms directly 
into the diamond lattice to enhance their functionality. In a previous paper, we sought 
to eliminate the need for conventional chemical methods by fabricating iron embedded 
magnetic NDs with great bio-compatibility via ion implantation15,23. In this paper, we 
present iron embedded magnetic NDs for use as an MRI contrast agent at room 
temperature with an existing commercial MRI scanner. In vivo experiments 
demonstrate that the proposed iron embedded magnetic NDs are indeed nontoxic and 
useful, thereby opening the door on the noninvasive tracking of NDs and the immense 
possibilities that this brings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results and Discussions 
 
In a previous paper, we illustrated the efficacy of iron embedded magnetic NDs (Fe-
NDs) for the in vitro enhancement of contrast in MRI images15. More advanced in vivo 
experiments require the dispersion of Fe-NDs in physiological solutions for injection 
into animals. Unfortunately, nanoparticles are highly susceptible to aggregation in 
physiological solutions24, which greatly increases the risk of side-effects. The use of 
albumin to facilitate the dispersion of nanoparticles in physiological solutions is well-
established25. Bovine serum albumin (BSA) has proven innocuous for mice25; therefore, 
we adopted BSA for the surface treatment and produced four samples: pure NDs, Fe-
NDs, NDs/BSA conjugates, and Fe-NDs/BSA conjugates. 
Fourier transform infrared spectroscopy (FTIR) was used to verify the attachment of 
the BSA. Figure 1 presents the FTIR absorbance spectra, as follows: (a) pure BSA (b) 
NDs/BSA conjugates, and (c) Fe-NDs/BSA conjugates. The amide characteristic 
peaks26 (amide I and amide II) clearly indicate the attachment of BSA on the surface. 
Dynamic light scattering (DLS) was used to measure the particle size distribution and 
zeta potential. Figure 2 (a) presents the particle size distribution of four samples with 
concentration 1 mg/ml. Without the BSA coating, pure NDs and Fe-NDs aggregated 
strongly in phosphate buffered saline (PBS) at the micrometer level. The attachment of 
BSA significantly reduced the average particle size in the PBS to less than 400 nm. 
Figure 2 (b) presents the corresponding zeta potential. The attachment of BSA increased 
the zeta potential, due to the electrically positive nature of BSA. This provided 
additional evidence of BSA surface attachment. Overall, these findings clearly 
demonstrate the efficacy of a BSA coating in enhancing dispersibility in the solution 
and preventing the aggregation. 
To obtain initial verification of the in vivo MRI contrast enhancement capability of 
Fe-NDs, 7T T2-weighted MR images were captured after performing simple 
intramuscular injection of the leg. Figure 3 presents axial and coronal T2-weighted 
images of C57BL/6 mice after injecting Fe-NDs (red arrow, left leg) and NDs (yellow 
arrow, right leg). The injection solutions containing the Fe-NDs or NDs caused the leg 
to swell with water. In T2-weighted images, higher water content results in images of 
greater brightness, which means that even if contrast enhancement does not occur, 
signal intensity from the leg area will become brighter after injection. We observed an 
obvious reduction in signal intensity in the area injected with Fe-NDs, indicating 
negative contrast enhancement. The untreated NDs did not produce obvious negative 
contrast enhancement. The success of contrast enhancement and the fact that the mice 
remained healthy and strong after the experiments prompted us to perform more 
advanced in vivo tests. 
Previous research exploring the biodistribution of NDs revealed that the injected 
NDs collect in the liver and remain there for a short period of time25,27. In our previous 
FTIR tests, there was no significant difference between the Fe-NDs and NDs in terms 
of surface profile, which suggests that the biodistribution is probably the same. We 
expected that the magnetic Fe-NDs would accumulate in the liver causing local 
inhomogeneities in the magnetic field, and this was the case in the experiments. Water 
protons in the liver were dephased by inhomogeneity in the magnetic field and the T2 
was shortened by additional spin-spin interactions. This led to a decrease in the signal 
intensity from the liver, resulting in a darker image, thereby physically confirming the 
contrast enhancement capability of Fe-NDs. 
In this work, intraperitoneal injection was used to observe negative contrast 
enhancement in the mice liver because it was very difficult for us to perform 
intravenous injection on mice. We initially intended to follow a protocol described in 
the literature27 in which the dose required for visualization is achieved through multiple 
intraperitoneal injections. Unfortunately, we were unable to secure the use of the MRI 
to perform scanning after each injection; therefore, we had to complete the in vivo 
experiments using a single high-dose injection. In the first round of experiments, we 
obtained T2-weighted mice MR images prior to injection, and then at one day and five 
days after injection. Two sets of samples were prepared. One contained only NDs/BSA 
conjugates. The other was Fe-NDs/BSA conjugates. Both sets were prepared at a 
concentration of 10 mg/ml. After sample injection, mouse behavior remained normal. 
Figure 4 presents T2-weighted C57BL/6 axial images of mice before treatment and at 
one day and five days after the injection of NDs or Fe-NDs. The Fe-NDs did not 
produce a significant increase in contrast in the original gray-level images (Figure 4 
(a)). After simple imaging processing (Figure 4 (b)), the livers of the mice presented a 
slight decrease in signal intensity (blue arrow) one day after Fe-NDs injection. No 
contrast enhancement was observed at five days after Fe-NDs injection, perhaps due to 
the elimination of Fe-NDs from the liver. This suggests that contrast enhancement can 
only be achieved between one and five days after injection. Thus, in the second round 
of experiments, all T2-weighted MR images were obtained prior to injection and at 
three days after injection. Three sets of samples were prepared for the second round of 
experiments. One set contained only PBS as a reference, the second set contained 
NDs/BSA conjugates (10 mg/ml), and the third set included Fe-NDs/BSA conjugates 
(10 mg/ml). After sample injection, mouse behavior remained normal. Figure 5 presents 
T2-weighted C57BL/6 images obtained before treatment and at three days after sample 
injection. The only sample that presented an obvious negative contrast enhancement 
was the one involving Fe-NDs injection (Figure 5 (c)). In that image, the liver could be 
distinguished easily and the boundary between the liver and muscle was very clear (red 
arrow). The accumulation of Fe-NDs in the liver created local magnetic field 
inhomogeneities, shortened the T2 value, and enhanced the negative contrast. Any 
contrast enhancement provided by regular NDs and PBS (Figure 5 (a) and (b)) was 
insignificant. 
To confirm the accumulation of NDs and Fe-NDs in the liver, further experiments 
were conducted on three new mice. This involved the intraperitoneal injection of PBS, 
NDs and Fe-NDs at the concentrations mentioned previously, whereupon the mice were 
sacrificed at three days after injection to obtain liver tissue for observation under 
microscope. Figure 6 presents the liver pathology in mice at three days after 
intraperitoneal administration. No nanoparticles were detected in livers injected with 
PBS (Figure 6 (a)). Large enough nanoparticle accumulations were clearly detected 
with red fluorescence in livers injected with NDs and Fe-NDs (Figure 6 (b) and (c)). 
The existence of NDs in the liver had little effect on MRI signal intensity (Figure 5 (b)), 
due to the non-magnetic nature of NDs. The accumulation of Fe-NDs in the liver (as 
observed in Figure 6 (c)) indicates that the change in signal intensity was due to Fe-
NDs injection. These findings verify the in vivo enhancement of contrast by Fe-NDs 
from a physical perspective. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
 
This paper demonstrates the in vivo enhancement of contrast through the injection of 
iron embedded magnetic NDs in images obtained using a typical commercial MRI 
scanner. This is the first research work on in vivo MRI contrast enhancement induced 
entirely by NDs. iron embedded magnetic NDs have considerable potential in imaging, 
targeted cancer therapy, and localized treatment all at the same time. Eventually, we 
hope that this new material, iron embedded magnetic NDs, will create or pave the way 
to cutting-edge new research topics which will help consolidate the study of prosperous 
NDs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods 
 
Fabrication of Iron embedded magnetic nanodiamonds. 
 
ND powder (average 100nm in diameter) from Microdiamant Co. was first dissolved 
in DI water. The solution was then applied onto an oxidized silicon wafer and dried. 
The wafer was iron-ion implanted with an energy 150 keV and dose 5x1015 atoms/cm2. 
The methods to remove the implanted NDs from the silicon wafer and to collect the 
iron embedded magnetic NDs have been described in our previous paper23. 
 
Preparation of Fe-NDs/BSA conjugates and NDs/BSA conjugates. 
 
Both Fe-NDs and NDs were purified and carboxylated to remove the surface graphite 
fractions and impurities with similar previously described methods28. The as received 
NDs and Fe-NDs were treated with a mixture solution of H2SO4 and HNO3 (volume 
ratio 9:1) at room temperature for 24 hours respectively. After reactions, the solutions 
were centrifuged to get purified Fe-NDs and NDs. Purified Fe-NDs and NDs were 
added into the 0.1 M NaOH solution at 90 °C for 2 hours and next 0.1 M HCl solution 
at 90 °C for 2 hours respectively. After reactions, the solutions were centrifuged to get 
carboxylated Fe-NDs and NDs. Both of them were washed many times with DI water 
to remove free acid. After drying process, 10 mg of carboxylated Fe-NDs and NDs were 
mixed together with 50 mg BSA powder from Sigma-Aldrich in 2 ml PBS respectively. 
After thorough mixing, the solutions were centrifuged and the sediment was washed 
several times to get Fe-NDs/BSA conjugates and NDs/BSA conjugates.  
 
FTIR measurement. 
 
To confirm the attachment of BSA, three samples, pure BSA, Fe-NDs/BSA 
conjugates and NDs/BSA conjugates were coated onto the silicon wafers and the 
absorbance of each samples were measured using a fourier transform infrared 
spectrometer (Bruker IFS66V/S). It is worth noting that silicon has no absorption within 
the measured range. 
 
 
 
 
 
 
Particle size distribution and Zeta potential measurement 
 
To understand the effect of the BSA attachment, four samples, Fe-NDs, NDs, Fe-
NDs/BSA conjugates and NDs/BSA conjugates, were dispersed in PBS with 
concentration 1 mg/ml. The particle size distribution and Zeta potential of all samples 
were measured using a Zetasizer Nano ZS from Malvern Instruments. 
 
In vivo MR imaging through intramuscular injection 
 
All animal experimental procedures and studies were approved by and in accordance 
with the Institutional Animal Care and Use Committee (IACUC) of National Tsing Hua 
University. The IACUC protocol number was 107028. The C57BL/6 mice (8-week-old 
male) were obtained from the Laboratory Animal Center of NAR Labs (NAR Labs, 
Taipei, Taiwan). Fe-NDs were dispersed in PBS containing 30% Matrigel from 
CORNING with concentration 2.4 mg/ml. Control sample was regular NDs with the 
same concentrations. Bruker BIOSPEC 70/30 MRI scanner equipped with proper 
gradient coils was used. RARE pulse sequence with TR = 2700 ms, TE = 26.7 ms, 
matrix size = 256 x 256, field of view = 40 x 40 mm2, slice thickness = 1 mm, an average 
of 4 was used to capture T2-weighted images. Fe-NDs and NDs samples were 
intramuscular injected into the left and right leg of mice respectively. T2-weighted 
images were performed from coronal and axial direction to see the contrast 
enhancement. 
 
 
In vivo MR imaging through intraperitoneal injection 
 
Fe-NDs/BSA conjugates was dispersed in PBS with concentration 10 mg/ml. Control 
samples were NDs/BSA conjugates with the same concentration and PBS. Bruker 
BIOSPEC 70/30 MRI scanner equipped with proper gradient coils was used. RARE 
pulse sequence with TR = 3100 ms, TE = 30 ms, matrix size = 256 x 256, field of view 
= 40 x 40 mm2, slice thickness = 0.5 mm, an average of 8 was used to capture liver T2-
weighted images. Following the pre-scan, Fe-NDs/BSA conjugates, control NDs/BSA 
conjugates and PBS samples 1 ml were intraperitoneal injected into the mice 
respectively. After absorption of planed days, liver T2-weighted images were 
performed again to see the contrast enhancement. 
 
 
 
Pathology and biodistribution 
 
NDs/BSA and Fe-NDs/BSA conjugates were dispersed in PBS buffer to a final 
concentration of 10 mg/ml and a volume of 1 ml was intraperitoneally injected into mice.  
After 72 hours, mice were sacrificed and the liver tissues were embedded in optimal 
cutting temperature compound and then stored in -80 ℃. The liver tissues were 
cryogenic-sectioned from transverse axis for 10 um in thickness. After fixation in -20 
℃ methanol for 5 minutes, the tissues were washed twice and then mounted by DAPI 
reagent (4',6-diamidino-2-phenylindole, Invitrogen) to visualize the nuclei. The 
biodistribution of the injected NDs and Fe-NDs were detected by its autofluorescence 
and visualized via microscope equipped with 605±55 nm filter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure captions 
 
 
 
 
Figure 1. Fourier Transform Infrared (FTIR) spectra (a) BSA, (b) NDs/BSA 
conjugates and (c) Fe-NDs/BSA conjugates. The amide characteristic peaks (amide I 
and amide II) clearly indicate the attachment of BSA on the surface of Fe-NDs and 
NDs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2. (a) Dynamic light scattering particle size measurements of NDs, Fe-NDs, 
NDs/BSA conjugates and Fe-NDs/BAS conjugates in PBS. NDs and Fe-NDs dispersed 
in PBS have a large aggregation size larger than 1000 nm. After BSA adsorption on the 
NDs/Fe-NDs surface, both NDs/BSA conjugates and Fe-NDs/BAS conjugates are 
better dispersed in PBS. (b) Zeta potential measurements of NDs, Fe-NDs, NDs/BSA 
conjugates and Fe-NDs/BAS conjugates in PBS. After BSA attachment, the zeta 
potentials increased due to the electric positive nature of BSA. 
  
Figure 3. (a) Axial and (b) coronal T2-weighted image with TR = 2700 ms and TE = 
26.7 ms after Fe-NDs (red, left leg) and NDs (yellow, right leg) intramuscular injection. 
Clear contrast enhancement was clearly observed at Fe-NDs injected left leg. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4. (a) Axial liver T2-weighted images with TR = 3100 ms and TE = 30 ms 
without imaging processing at different time after NDs and Fe-NDs intraperitoneal 
injection. (b) Corresponding axial liver T2-weighted images with imaging processing. 
Images are shown pre, a day and 5 days after injection. Negative contrast enhancement 
was observed at Fe-NDs injected mouse after imaging processing. 
 
 
 
 
 
 
  
Figure 5. Axial liver T2-weighted images with TR = 3100 ms and TE = 30 ms after (a) 
PBS, (b) NDs and (c) Fe-NDs 3 days intraperitoneal injection. Clear negative contrast 
enhancement was clearly observed at Fe-NDs injected mouse. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 6. Mice liver bright field pathology, corresponding DAPI staining and red 
fluorescence images after (a) PBS, (b) NDs and (c) Fe-NDs 3 days intraperitoneal 
injection. Nanoparticle accumulations were clearly observed in livers injected with 
NDs and Fe-NDs. Scale bar: 100 μm. 
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